'Eastern cooperative oncology group' diaporamas de présentation

NOTE FOR HEALTHCARE PROFESSIONAL

NOTE FOR HEALTHCARE PROFESSIONAL. This presentation has been provided to you upon request. If presenting this to other healthcare professionals, GSK advises that you use the presentation in full to ensure a fair balance of information, both efficacy and safety.

843 views • 70 slides

Treatment in Advanced Non-Small Cell Lung Cancer

Treatment in Advanced Non-Small Cell Lung Cancer. NSCLC| Epidemiology- Australia. 5 th most commonly diagnosed cancer in Australia 8.9% of new cancer diagnoses In 2009: 10,193 cases ( 6034 men, 4159 women) Projection to 2020 ? 13,640 Mortality

789 views • 49 slides

NOTE FOR HEALTHCARE PROFESSIONAL

NOTE FOR HEALTHCARE PROFESSIONAL. This presentation has been provided to you upon request. If presenting this to other healthcare professionals, GSK advises that you use the presentation in full to ensure a fair balance of information, both efficacy and safety.

564 views • 44 slides

Acquired Resistance to EGFR TKIs: What Is It and How Do We Treat?

Acquired Resistance to EGFR TKIs: What Is It and How Do We Treat?. Vincent A Miller, MD Thoracic Oncology Service Memorial Sloan-Kettering Cancer Center. Disclosure Slide. Background. Patients with CML and GIST have a high rate of response to treatment with imatinib.

1.31k views • 37 slides

788 views • 37 slides

Timing of Transplant for Multiple Myeloma

Timing of Transplant for Multiple Myeloma. Robert Z. Orlowski, Ph.D., M.D. Director, Myeloma Section Professor, Departments of Lymphoma/Myeloma & Experimental Therapeutics Principal Investigator, M. D. Anderson SPORE in Multiple Myeloma Chair, Southwest Oncology Group Myeloma Committee.

604 views • 37 slides

Novel Biologic Therapies for Second-Line Gastric Cancer

Novel Biologic Therapies for Second-Line Gastric Cancer. Charles S. Fuchs, MD Dana-Farber Cancer Institute Harvard Medical School Boston, MA. Second-Line Therapy in Gastric Cancer. No approved 2 nd -line chemotherapy 20-40% patients receiving 1 st -line therapy receive 2 nd - line

738 views • 36 slides

Clinically Meaningful Change and Clinical Relevance of the Functional Assessment of Cancer Therapy-Lung: Analysis of ECO

Clinically Meaningful Change and Clinical Relevance of the Functional Assessment of Cancer Therapy-Lung: Analysis of ECOG 5592 Data. David Cella & David T. Eton, Evanston Northwestern Healthcare & Northwestern University Diane L. Fairclough, AMC Cancer Research Center

561 views • 35 slides

Job code: Eribulin-EU2095 Date of prep: July 2011

555 views • 29 slides

1. Baselga et al . N Engl J Med 2011

A Phase III, Randomized, Double-Blind, Placebo-Controlled Registration Trial to Evaluate the Efficacy and Safety of Placebo + Trastuzumab + Docetaxel vs. Pertuzumab + Trastuzumab + Docetaxel in Patients with Previously Untreated HER2-Positive Metastatic Breast Cancer (CLEOPATRA).

407 views • 23 slides

Cancer Clinical Trials Aimed at Decreasing Toxicity

Cancer Clinical Trials Aimed at Decreasing Toxicity . The key goals of this workshop are to:. 1) recommend best (preclinical) practices for efficiently evaluating and developing agents in the CMCR pipeline for possible applications in cancer patients

370 views • 22 slides

Phase III CORRECT trial of regorafenib in metastatic colorectal cancer ( mCRC )

Phase III CORRECT trial of regorafenib in metastatic colorectal cancer ( mCRC ). Eric Van Cutsem, MD, PhD University Hospitals Gasthuisberg /Leuven, Leuven, Belgium. On behalf of:

1.7k views • 22 slides

Cancer Clinical Trials Aimed at Decreasing Toxicity

Cancer Clinical Trials Aimed at Decreasing Toxicity. The key goals of this workshop are to:. 1) recommend best (preclinical) practices for efficiently evaluating and developing agents in the CMCR pipeline for possible applications in cancer patients

224 views • 22 slides

Nutritional Strategies for Managing Side Effects During Cancer Treatment

Nutritional Strategies for Managing Side Effects During Cancer Treatment. Presentation Agenda. Importance of nutrition Prevalence of side effects Nutritional strategies. Feel better Fight fatigue Maintain body weight and nutrient stores.

544 views • 20 slides

LBA9094

LBA9094. The ultra-low-molecular-weight heparin (ULMWH) semuloparin for prevention of venous thromboembolism (VTE) in cancer patients receiving chemotherapy: SAVE-ONCO study.

398 views • 19 slides

Phase-III Studie: HECTOR Topotecan plus Carboplatin (Paclitaxel plus Carboplatin oder Gemcitabin plus Carboplatin)

AGO-Austria. Phase-III Studie: HECTOR Topotecan plus Carboplatin (Paclitaxel plus Carboplatin oder Gemcitabin plus Carboplatin) Intergroup Study of NOGGO und Studiengruppe Ovar (NOGGO-R9, AGO Ovar 2.12) AGO-Austria, GEICO.

387 views • 17 slides

A Phase I Trial of Scutellaria Barbata (BZL101) for Metastatic Breast Cancer

A Phase I Trial of Scutellaria Barbata (BZL101) for Metastatic Breast Cancer Perez A 1 , Shaw HS 2 , Fleming G 3 , Hershman D 4 , Franco S 1 , Shapiro C 5 , Neal K 6 , Caygill K 6 , Cohen I 6 , Tagliaferri M 6 , Tripathy D 7 .

39 views • 1 slides

Figure 3 A patient with a metastatic nonfunctional carcinoid tumor, Eastern Cooperative Oncology Group performance status 0, with bulky liver disease, which illustrates the tropism of NETs for the liver.

137 views • 1 slides